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Abstract
Genetic suppressor elements (GSEs) are biomolecules derived from a gene or genome of interest that act as transdominant
inhibitors of biological functions presumably by disruption of critical biological interfaces. We exploited a cell death reporter
cell line for hepatitis C virus (HCV) infection, n4mBid, to develop an iterative selection/enrichment strategy for the
identification of anti-HCV GSEs. Using this approach, a library of fragments of an HCV genome was screened for sequences
that suppress HCV infection. A 244 amino acid gene fragment, B1, was strongly enriched after 5 rounds of selection. B1
derives from a single-base frameshift of the enhanced green fluorescent protein (eGFP) which was used as a filler during
fragment cloning. B1 has a very high net positive charge of 43 at neutral pH and a high charge-to-mass (kDa) ratio of 1.5. We
show that B1 expression specifically inhibits HCV replication. In addition, five highly positively charged B1 fragments
produced from progressive truncation at the C-terminus all retain the ability to inhibit HCV, suggesting that a high positive
charge, rather than a particular motif in B1, likely accounts for B1’s anti-HCV activity. Another supercharged protein, +36GFP,
was also found to strongly inhibit HCV replication when added to cells at the time of infection. This study reports a new
methodology for HCV inhibitor screening and points to the anti-HCV potential of positively charged proteins/peptides.
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Introduction
Hepatitis C virus (HCV) is a single-stranded, enveloped,
positive-sense RNA virus of the Flaviviridae family [1]. HCV
RNA polymerase exhibits a high mutation rate, causing the virus
to exist as a quasispecies in a single patient [2]. Six major
genotypes and numerous subtypes of HCV have been identified
around the world [3]. HCV infection afflicts over 180 million
people worldwide [4] and is the leading cause of cirrhosis and
cancer of the liver [5,6]. HCV-induced end-stage liver disease is
the leading indication for liver transplantation in developed
countries [7]. Until recently the only approved HCV therapy
involved a 24 or 48 week regimen of combination therapy using
pegylated interferon alpha and ribavirin [8,9]. Interferon alpha-
ribavirin mono-treatment is costly, time-consuming and riddled
with serious and debilitating side effects such as depression, fatigue
and flu-like symptoms [10,11], resulting in many patients being
unable to complete the therapy. In addition, interferon a-ribavirin
therapy yields a sustained virological response (SVR) in only 50%
of treated patients infected with the most common genotype [12].
Recent pharmacological advances have led to the development
and approval of two new drugs, boceprevir and telaprevir, which
greatly improve the treatment response to up to 79% of the
patients [13,14]. However, molecules that target specific viral
proteins, including boceprevir, telaprevir and most of those in
advanced clinical development, tend to foster drug-resistant
variants [15,16].
Genetic suppressor elements (GSEs) are short, biologically
active gene fragments derived from a gene or genome of interest
that act as transdominant inhibitors of biological functions [17,18].
GSEs can exert their inhibitory effect through expressed antisense
RNAs, structural RNAs, or peptide/protein fragments that bind to
and disrupt critical biological interfaces. Screens or selections for
GSEs typically do not require any previous knowledge of target
gene(s)/protein(s) or the type of inhibitor (antisense RNAs, RNA
decoys or transdominant mutants) that will most potently suppress
the function of a specific gene. This feature of GSE screens/
selections has empowered the approach to identify previously
unknown viral genes that are essential for the infectious cycle of
bacteriophage lambda [19]. Thus, the performance of GSE
screens/selections has the potential to uncover new biological
information even in a very thoroughly investigated system. Other
successes of GSE selection include the elucidation of human
immunodeficiency virus type 1 (HIV-1) latency [17], bovine viral
diarrhea virus entry [20], tumor suppressor genes [21], genes that
mediate cellular sensitivity to anticancer drugs [22,23], regulators
of transcription [24], and potential anticancer [25] and antiviral
[26] targets.
In addition to their role as tools for studying viruses, GSEs are
potential therapeutic agents. Some GSEs have been found to
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decrease viral loads of bovine viral diarrhea virus (BVDV) by 100-
to 1000-fold [20], a potency on par with some of the most potent
BVDV antiviral candidates in preclinical and clinical trials [27].
Even if the GSEs themselves are not ideal drugs, the molecules can
serve as templates for the creation of small molecule mimetics,
which can in turn be used as antivirals.
In this work we aimed to identify GSEs with anti-HCV activity.
Using a hepatoma cell line, n4mBid, that reports HCV infection
by a cell-death phenotype. Specifically, we developed an iterative
selection strategy which gradually enriches anti-HCV genetic
fragments that confer resistance to HCV-induced cell death.
Surprisingly, the most strongly enriched element, a genetic
element we named B1, is a 244 amino acid protein derived from
a frame shifted enhanced green fluorescent protein (eGFP) [28]
that was used as a filler during library cloning. B1 has a high net
positive charge of 43 at pH 7, leading to a charge-to-molecular-
weight ratio of 1.5. B1 also possesses strong ability to deliver
protein/nucleic acid cargo into the mammalian cell cytosol [29].
In this work, we show that B1 inhibits HCV replication when
expressed intracellularly and the inhibitory effect is largely
mediated by its high overall charge.
Results
GSE screens to identify genes involved in HCV
infection. A schematic of the approach used for GSE selection
is presented in Figure 1. DNA fragments sized in the range 100–
200 bp were obtained by DNaseI digestion of a plasmid encoding
full-length Jc1 HCV [30]. These fragments were first polished to
form blunt ends and then cloned into the lentiviral vector pV1 at
the PmeI restriction site. pV1 is a minimal HIV-1 provirus lacking
most HIV genes except for all necessary cis acting sequences such
as Tat, Rev and Vpu ORF [31]. pV1 also lacks a Nef gene and in
its place contains a cloning site for the insertion and expression of
the cDNA of interest. cDNA inserts are expressed from the viral
LTR. We chose the pV1 for library expression because viral
particles can be repackaged from pV1-transduced cells when these
cells are transfected with vectors encoding envelope glycoprotein
and HIV gag-pol, facilitating the enrichment of selected GSEs
[32].
In this study, the fragmented library was expressed as a C-
terminal fusion to the transmembrane anchor of HCV NS4A
(NS4Am) [33]. HCV replicates in complexes associated with the
lipid raft membrane [34,35] and HCV nonstructural (NS) proteins
have been detected around lipid droplets in most HCV-permissive
cells [36]. The attachment of the membrane-anchoring domain
from a HCV NS protein to library fragments is designed to
facilitate the interaction of the library fragments with viral/host
factors located in the vicinity of the replication complexes, thus
increasing the likelihood of successful identification of suppressor
elements.
A randomly fragmented HCV genome was cloned into pV1 and
this library was packaged into lentiviral particles via transfection of
a packaging cell line. The lentiviral library was used to transduce
the HCV reporter cell line n4mBid at a low multiplicity of
infection (MOI) such that most transduced cells receive only one
library fragment. The n4mBid cells contain a modified version of
the pro-apoptotic protein Bid (mBid) and undergo apoptosis upon
intracellular expression of HCV serine protease NS3-4A [37].
Two days post transduction, after the expression of the fragment
library is established, these cells were infected with the Jc1 isolate
of cell-culture-produced HCV (HCVcc) (MOI ,1) [30] and
maintained for a period of 9 days or until .90% of the cells
succumbed to the HCV- induced cytopathic effect. The surviving
cells were ‘cured’ of any ongoing HCV infection by exposure to
the nucleoside analog 29C-MA (1 mM) [38]. Library fragments
present in the surviving cells were repackaged by transfection of
these cells with plasmids encoding Gag-pol and VSV-G envelope
protein. Repackaged lentiviruses were used in the subsequent
round of selection (Figure 1A). In some cases, the repackaged
viruses were amplified in 293T cells to increase the viral titer prior
to the next round of selection.
In total, we screened a library containing an estimated 12, 000
individual fragments. For a library based on a fragmented
retroviral HIV genome, the frequency of active perturbations
(i.e. desirable GSE molecules) was estimated to be ,1/6000 [17].
As shown in Figure 1B, the time taken to observe the cytopathic
phenotype, as well as the percentage of surviving cells at the end of
the selection, increased with each successive round of selection,
suggesting that HCV-inhibitory fragments were being enriched. At
the end of the fifth round of selection, library fragments were
recovered from the repackaged lentivirus and the inserts were
expressed as cDNA via RT-PCR. We observed significant
enrichment of a fragment of ,800 bp, and weaker enrichment
several fragments with sizes below 500 bp (Figure 1C). The
800 bp fragment was recovered and named B1. Sequencing
revealed that B1 is a NS4Am-eGFP fusion gene with a single-
nucleotide insertion at the 39 end of NS4Am just upstream of
eGFP that results in a frame-shift of the eGFP gene (Figure S1).
Although eGFP was not included in the fragment library by
design, it was present in the vector that was used as the basis for
cloning of the fragment library and was removed by restriction
enzyme digestion prior to cloning. It is apparent that a small
amount of the original eGFP-containing vector that additionally
contained a frameshift-causing base insertion remained in the
cloned library mixture. The frame-shifted eGFP gene yields a
protein of 244 amino acids with a very high net positive charge of
+43. The smaller enriched fragments shown in Figure 1C did not
significantly inhibit Jc1 Gluc HCVcc (data not shown) and were
not investigated further.
To confirm the expression of full-length B1 in Huh-7.5 cells, we
constructed Flag-tagged B1 both with and without the NS4Am
anchor (constructs 3 and 4 in Table 1; Figure 2A). The expression
levels of the Flag-NS4Am-B1 appeared to be slightly lower than
that of Flag-B1. We next determined the intracellular localization
of both constructs using confocal microscopy. It was expected that
Flag-NS4Am-B1 would be localized to the endoplasmic reticulum
(ER) by the presence of the NS4Am membrane anchor. However,
both Flag-NS4Am-B1 and Flag-B1 appeared to be predominantly
localized to the cell nucleus and concentrated in nucleolar regions
(Figure 2B). Flag-NS4Am-eGFP localized to an extra-nuclear
space consistent with ER association (Figure S2A). Since no known
nuclear localization signal is present in B1, we reason that the
nuclear localization may derive from a tendency of B1 to associate
with negatively charged genomic DNA during cell division.
Intracellular B1 Inhibits HCV Infection
To assess the ability of B1 to inhibit HCV infection, the
sequences of B1, NS4Am-B1 and eGFP were cloned into pLenti6
proviruses and packaged into pseudoparticles used to transduce
naı¨ve Huh-7.5 cells at MOI ,1. After selection with blasticidin,
the transduced cell populations were inoculated with Jc1 Gluc
HCVcc [39], HIV-1 lentivirus pseudotyped with envelope protein
from H77 HCV (H77pp) [40], or HIV-1 lentivirus pseudotyped
with vesicular stomatitis virus glycoprotein (VSV-Gpp) [41]. As
shown in Figure 3A, cells expressing either NS4Am-B1 or B1
exhibited reduced levels of Jc1 Gluc HCVcc [30] when compared
to those expressing eGFP, confirming the ability of B1 to inhibit
HCV infection. B1 did not detectably inhibit viral entry in cells
Screen Identified Supercharged Anti-HCV Protein
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inoculated with pseudotyped lentiviruses regardless of the envelope
protein. The pseudotyped lentiviruses are able to enter cells but
are unable to replicate. These results suggest that B1 does not
affect the entry step of HCV infection or lentiviral transduction.
Since B1 appears to predominantly localize to the nucleus, and
some nuclear factors are required for HCV replication [42–44],
we next considered whether B1 inhibits HCV replication. Cell
populations expressing NS4Am-eGFP or NS4Am-B1 were elec-
troporated with RNA encoding either full-length Jc1 Gluc HCVcc
[30]. The amount of intracellular HCV RNA was quantified 48
hours post electroporation by qRT-PCR. Similar levels of
inhibition were observed in cells electroporated with Jc1 Gluc
HCVcc [30] (Figure 3B) and in cells infected with the same virus
(Figure 3A). No inhibition of HCV H77 replicon was observed
Figure 1. Overview of GSE selection. (A) GSE selection scheme. Randomly fragmented libraries were prepared by limited digestion of the HCV
genome and fragments of 100–200 bp were cloned into the lentiviral vector pV1 and packaged into VSV-G-pseudotyped lentiviral particles. Library
pseudoparticles were delivered into n4mBid cells such that each library fragment was expressed on average in at least 1000 cells. These cells were
then infected with HCV and passaged for a period of 9 days or until the number of surviving cells was #10% of the initial cell population. The specific
HCV inhibitor 29C-MA was then added to rescue the surviving cells. Library fragments were repackaged by transfecting the surviving cells with
plasmids encoding VSV-G and HIV gag-pol and formed the basis of subsequent rounds of selection. (B) Table depicting the number of cells that
survived the HCV challenge as a percentage of the total number of seeded cells during consecutive rounds of selection. (C) Agarose gel image of
cDNA inserts harvested from repackaged pseudoparticles after 5 rounds of selection.
doi:10.1371/journal.pone.0084022.g001
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(data not shown), suggesting that the effect of B1 may be limited to
genotype 2 HCV.
Next, we considered whether B1 might inhibit the translation/
processing of HCV because 1) B1 was previously found to strongly
associate with mRNA due to its high positive charge [45] and 2)
B1 primarily localizes to the nucleus and HCV translation is
potentially modulated by nuclear factors [42,43]. Cell populations
expressing NS4Am-GFP or NS4Am-B1 were transfected with
RNA expressing the full length Jc1 Gluc HCVcc [30].HCV IRES-
mediated translation was quantified based on reporter activity
measured at 5 hours post transfection (prior to the onset of
replication [46]). No inhibition of Jc1 Gluc HCVcc translation was
observed in cells expressing NS4Am-B1 (Figure 3C), indicating
that B1 does not affect IRES-mediated translation.
B1 does not affect lentiviral transduction (Figure 3A), suggesting
that B1 likely does not upregulate non-specific antiviral response
mechanisms such as the interferon pathway or the unfolded
protein response [47,48]. To confirm that B1 does not activate the
innate antiviral machinery, we determined the ability of B1 to
inhibit the infection of Sindbis Virus (SINV), a closely related
positive sense RNA virus belonging to the Alphavirus genus [49].
No inhibition of SINV was observed in cells expressing B1
(Figure 3D), supporting our hypothesis that SINV likely does not
activate general cellular antiviral pathways.
Shortened Positively Charged Forms of B1 Retain Anti-
HCV Activity
Next, we sought to determine whether a specific domain/region
in B1 is responsible for the anti-HCV activity. B1 was
progressively truncated at the C-terminus to form the shortened
versions named B2– B6 (Figure 4A). Truncation sites were chosen
such that they do not disrupt secondary structural motifs predicted
by the GOR4 algorithm [50]. These shortened B1 fragments were
cloned into the pV1 lentiviral vector and packaged into
lentiviruses. Huh-7.5 cell populations expressing the shortened
B1 fragments were challenged with Jc1 Gluc HCVcc at MOI
,0.1 and the HCV infection levels were quantified 3 days post
infection. All shortened B1 constructs appeared to inhibit HCV
infection to a level comparable to the full-length B1 (Figure 4B),
indicating that no specific region/domain in B1 is singly
responsible for the anti-HCV activity. Fragments with a positive
charge above 17 all suppressed HCV activity by .50%, while B6,
the shortest fragment with a lower predicted charge of +11,
exhibited slightly reduced anti-HCV activity. The negative control
protein eGFP, with a predicted net charge of 28, showed no anti-
HCV activity.
Discussion
In this work we report the development of a selection method
for the identification of genetic suppressor elements (GSEs) of
HCV and characterize the anti-HCV properties of a highly
enriched GSE from our application of the selection. Despite recent
advances in direct acting antivirals (DAAs) against HCV, there
remains a critical need for new HCV inhibitors with novel
mechanisms of antiviral action. The selection method we
developed utilizes a cell-death reporter hepatoma cell line for
HCV previously developed in our laboratory, n4mBid [37]. A
fragmented HCV genomic library is delivered to n4mBid cells via
lentiviral transduction. Transduced cells are subsequently chal-
lenged with cell-culture-produced HCV (HCVcc) [30]. The






1 NS4Am-B1 30.6 pV1, pLenti6
2 B1 28.4 pV1, pLenti6
3 Flag-NS4Am-B1 33.3 pZsGreen
4 Flag-B1 31.1 pZsGreen
5 NS4Am-B2 17.8 pV1
6 NS4Am-B3 14.7 pV1
7 NS4Am-B4 13.2 pV1
8 NS4Am-B5 10.7 pV1
9 NS4Am-B6 6 pV1
10 +36GFP 28.4 pV1
11 NS4Am-eGFP 30.6 pv1
doi:10.1371/journal.pone.0084022.t001
Figure 2. Expression of B1 in Huh-7.5 cells. (A) Western blot of Flag-NS4Am-B1 and Flag-B1. (B) Confocal microscopic images of Huh-7.5 cells
stably expressing Flag-NS4Am-B1 or Flag-B1 after immunohistochemical staining with anti-flag antibody.
doi:10.1371/journal.pone.0084022.g002
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Figure 3. B1 inhibits HCV infection. (A) Cells expressing B1 or NS4Am-B1 are less permissive to HCV infection. Huh 7.5 cells were transduced with
lentiviral pseudoparticles encoding eGFP, NS4Am-B1 or B1 at MOI ,1 and selected for stable transductants prior to infection with JC1 Gluc HCVcc
(MOI ,0.1), H77 HCVpp (10-fold dilution) or VSV-Gpp (500-fold dilution) for 12 hours. The supernatant Gluc activity was quantified 24 hours later and
used as indication of HCV infection level. (B) Cells expressing NS4Am-B1 suppress HCV replication. Huh-7.5 cells were transduced with lentiviral
pseudoparticles encoding NS4Am-eGFP or NS4Am-B1 at MOI 4. 48 hours later, these cells were electroporated with RNA of full-length JC1 Gluc
HCVcc. Intracellular HCV RNA levels were quantified 48 hours later using qRT-PCR. (C) B1 does not inhibit HCV translation. Naı¨ve Huh-7.5 cells or cell
populations expressing NS4Am-B1 (as in B) were electroporated with JC1 Gluc HCVcc. HCV translation was quantified by measuring the activity of
secreted Gluc 5 hours later. (D) B1 does not inhibit SINV infection. BHK-J cells were transduced with lentiviral pseudoparticles encoding NS4Am-B1 or
NS4Am alone at MOI ,4. Two days later, cells were infected with SINV for 12 hours and thoroughly washed. Infectious SINV in the supernatant
collected 48 hours later were quantified by plaque assay. All error bars represent the standard deviation of two independent experiments carried out
in duplicate.
doi:10.1371/journal.pone.0084022.g003
Figure 4. Shortened forms of B1 retain significant anti-HCV activity. (A) B1 was progressively truncated from the C-terminus to form the
constructs B2– B6 without the disruption of secondary structural motifs predicted by the GOR4 algorithm. (B) Anti-HCV activity of constructs B1– B6.
Huh-7.5 cells were transduced with lentiviral pseudoparticles encoding the indicated constructs at MOI ,4. 48 hours later, these cells were infected
overnight with JC1 Gluc HCVcc (MOI ,0.1). Supernatant Gluc activities were quantified 48 hours later and used as indication of HCV infection level.
Error bars represent the standard deviation of two independent experiments carried out in duplicate.
doi:10.1371/journal.pone.0084022.g004
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surviving cells are pooled and the enriched genetic elements from
these cells are harvested, repackaged, and used in subsequent
rounds of selection/enrichment.
After 5 rounds of selection, we identified B1, a 244 amino acid
protein derived from a rare frameshift-causing single-base
insertion present immediately upstream of an enhanced GFP
(eGFP) gene, a filler used during library cloning. B1 is highly
positively charged and has been found to possesses the ability to
penetrate and deliver biomolecular cargo into cells [45]. The
eGFP sequence was not intended to be a part of the original
library. It is even more unexpected that B1 derives from a single
nucleotide insertion in the primer region upstream of eGFP
(Figure S1). We showed that B1 is expressed as a full-length
protein in Huh-7.5 cells (Figure 2A. Surprisingly, fluorescence
microscopic images showed that B1 appeared to be almost
exclusively localized in the nucleus even when fused to the NS4A
membrane anchor (NS4Am) (Figure 2B). It is possible that an
undetectable amount of B1 remains in the cytosol. Despite the
nuclear localization, both unmodified B1 and NS4Am-B1 exhibit
a similar anti-HCV potency (Figure 3A). Further characterization
revealed that B1 does not affect HCV entry (Figure 3A) or virus
production (data not shown) but specifically inhibits the replication
step of the HCV life cycle (Figure 3B). Some nuclear factors such
as heterologous nuclear ribonucleoprotein L (hnRNP L) [42] and
the nuclear La protein [43] have been demonstrated to affect
HCV replication by upregulating HCV translation. However, B1
does not appear to inhibit IRES-mediated HCV translation
(Figure 3C). Recently, it was shown that nuclear translocation of
HCV NS5A regulates HCV replication [51]. The antiviral
mechanism of action of B1 remains enigmatic. We speculate that
B1’s ability to inhibit HCV replication may be attributable to the
presence of a small amount of B1 in the cytosol and/or interaction
of B1 with nuclear factors required for HCV replication.
To shed light on B1’s mechanism of anti-HCV action, a series of
shortened B1 constructs with progressive deletions at the C-
terminus were generated. We reasoned that, if the high net positive
charge of B1 was not a major factor contributing to the anti-HCV
activity and the inhibition is due instead to a specific structural
motif or region in B1, then once the motif was removed from the
construct, anti-HCV activity should be completely abrogated. We
generated shortened forms of B1 with predicted net charges
ranging from +11 to +39 and showed that all these fragments,
including the shortest fragment (35 amino acids with a predicted
charge +11), retained most, if not all, of the anti-HCV activity of
the parent construct B1 (Figure 4B). This result suggests that the
high net positive charge, rather than a specific motif, could be
responsible for the anti-HCV activity of B1.
While positively charged proteins are relatively uncommon in
nature, many are expressed in mammalian cells [52]. Previously,
Liu and coworkers synthesized a series supercharged variants of
GFP and showed that these molecules can effectively transduce
mammalian cells [53]. We tested the ability of one of these
supercharged proteins, +36 GFP, to inhibit HCV infection.
+36GFP possesses a net positive charge of +39 and as such is
comparable to B1 in overall charge. Fluorescence imaging of
intracellularly expressed +36GFP indicated that it was predomi-
nantly localized in the cell nucleus (Figure S2A), similar to B1
(Figure 2B). However, even after high-MOI transduction (up to
MOI ,10), only a small percentage (,20%) of the transduced
cells showed detectable +36GFP expression (Figure S3B). Perhaps
for this reason, no HCV inhibition was observed in cells
transduced with a vector expressing +36GFP (Figure S2C).
Interestingly, in contrast, cells exposed to purified recombinant
B1 and +36GFP at the time of infection showed a reversed
phenotype. Purified B1 added extracellularly to cells at the same
time of HCV or lentivirus did not inhibit infection, while
extracellularly added +36GFP strongly inhibited HCV infection
and partially inhibited VSV-Gpp infection (Figure S3). The
discrepancy between the anti-HCV profiles of B1 and +36GFP on
intracellular expression vs. after extracellular exposure may derive
in part from a different direct action of the two molecules on
extracellular virus and in part from the different intracellular
distributions of the molecules produced from the two delivery
methods. Intracellularly expressed B1 (Figure 2B) and +36GFP
(Figure S2A) both localize to the nucleus. In contrast, extracellu-
larly delivered B1 exhibits a punctate distribution on the
paranuclear region of cells, while extracellularly delivered
+36GFP accumulates evenly in a large number of tiny, endosomal
compartments [45].
Taken at face value, the anti-HCV activity of B1 is comparable
to the antiviral effects of defensins. Defensins are short (less than
100 amino acids), positively charged peptides that contain six
cysteine residues [54]. Defensins are broad-spectrum antimicrobi-
als and have been shown to be active against bacteria, fungi and
some enveloped viruses [55–59]. The antiviral activity of defensins
is largely attributed to the molecules’ positive charge [56].
However, defensins act directly on extracellular viruses while B1
inhibits intracellular HCV replication (Figure 3B). Exposing cells
to purified B1 protein prior to or during HCV infection did not
yield HCV inhibition (Figure S3). Extracellularly delivered B1
exhibited a punctate distribution in the paranuclear region of cells
[29], comparable to the distribution of extracellularly delivered
+36GFP [60]. However, intracellularly expressed B1 appeared to
exclusively localize to the nucleus (Figure 2B). The difference in
subcellular localization of B1 may be critical to the molecule’s
ability to inhibit HCV replication. Human alpha defensins 1–3
were found to act intracellularly to inhibit PKC signaling, which
results in inhibition of HIV infection [61]. However, no inhibition
of pseudotyped lentivirus was observed in cells expressing B1
(Figure 3A), suggesting that B1 does not significantly inhibit PKC
signaling and B1 does not function like a defensin in these cells. In
contrast, extracellularly delivered +36GFP did significantly inhibit
HCV and pseudotyped lentivirus infection (Figure S3), implying
that unlike B1, recombinant +36GFP may possess some defensin-
like antiviral activity.
In conclusion we developed an in vitro method for selecting
GSEs of HCV. Application of this selection led to the unexpected
identification of a highly positively charged protein, B1, which
inhibits HCV replication. Although B1 does not exist in nature,
and cannot be generated by a frame shift of any natural proteins, it
is potentially usefully useful for biomedical applications due to 1)
its ability to inhibit HCV replication and 2) mediate protein
transduction [45]. Minimization studies showed that B1’s anti-
HCV activity is not entirely attributable to any specific region of
the molecule, while shortened positively charged variants of B1 all
retained some anti-HCV activity, suggesting a general role of a
high net positive charge in the antiviral activity. Follow-up studies
showed that another highly positively charged protein, +36GFP,
also possesses anti-HCV activity, although these preliminary
studies point to a potentially different antiviral mode of action of
+36GFP relative to B1 when added extracellularly to cells at the
time of infection. Proteins with high net positive charge represent a
novel class of anti-HCV molecules. In addition, the GSE selection
approach described in this report can be applied to other protein/
peptide libraries in the continued search for new HCV-inhibitory
molecules.
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Materials and Methods
Reagents, Bacterial Strains and Cell Lines
TZM-bl cells were obtained from Dr. John C. Kappes, Dr.
Xiaoyun Wu and Tranzyme Inc. through the NIH AIDS Reagent
Program, Division of AIDS, NIAID [62]. Huh-7 and Huh-7.5
cells [63] were obtained from Prof. Charles Rice (Rockefeller
University). 293T cells were purchased from Life Technologies
(Grand Island, NY).
All cell lines were cultured in complete growth medium
(Dulbecco’s Modified Eagle Medium (DMEM) containing
4500 mg/L glucose, 4.0 mM L- Glutamine, and 110 mg/L
sodium pyruvate (Thermo Scientific HyClone, Logan, UT)
supplemented with 10% fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA) and 1X non- essential amino acids (Thermo
Scientific HyClone, Logan, UT)). Escherichia coli strains DH5a and
Stbl3 (Life technologies) were used for recombinant DNA cloning.
Biolux Gaussia Luciferase Assay Kit was purchased from New
England Biolabs (Ipswich, MA). Dulbecco’s Phosphate Buffered
Saline (DPBS) was purchased from Thermo Scientific HyClone.
OptiMEM and Lipofectamine 2000 were purchased from Life
Technologies. Luria- Bertani (LB) broth, Mirus TransIT LT1
transfection reagent and ampicillin were obtained from Thermo
Fisher Scientific. 0.25% trypsin- EDTA was from VWR Interna-
tional. All restriction enzymes, nucleases and polymerase were
purchased from New England Biolabs.
Fragment Library Preparation
Plasmid DNA encoding full-length Jc1-NFlag2 HCVcc [30] was
digested with DNaseI at 16uC for minutes to obtain an average
fragments size between 100–200 bp. The digested DNA were
extracted by phenol-chloroform following standard protocol,
sequentially treated with Mung Bean Nuclease, T4 DNA
polymerase and Klenow Fragments to form blunt ends, and
phosphorylated using T4 Polynucletide Kinase. Blunted fragments
were inserted into the pV1 lentiviral vector downstream of NS4A
membrane anchoring domain (NS4Am). pV1 is a minimal HIV-1
provirus lacking most of the HIV genes except for essential cis-
acting elements and the tat, rev and vpu genes [64]. The vector
backbone was prepared by digesting pV1-NS4Am-eGFP with
PmeI to remove the eGFP insert and dephosphorylated using
Antarctic Phosphotase. The ligation mixture was electroporated
into E. coli DH5a. Colonies (,12,000) were pooled and cultured,
and the plasmid DNA library (Lib4) was isolated.
Lentiviral Pseudoparticle Production and Titering
Lib4-expressing pseudoparticles (Lib4pp) were generated based
on a procedure described previously [65]. Briefly, 293T cells were
transfected with a 2:2:1 mass ratio of plasmids encoding HIV gag-
pol, vesicular stomatitis virus glycoprotein (VSV-G), and Lib4
using TransIT-LT1 transfection reagent [66]. Cell supernatants
containing VSV-G-coated Lib4pp were collected 48 hours later,
filtered and stored at 280uC until use. Collected Lib4pp were
titered in TZM-bl indicator cells. TZM-bl cells were inoculated
with serial dilutions of Lib4pp (1021–1026). 48 hours later, cells
were washed with DPBS, fixed in PBS/2% paraformaldehyde
(PFA) and stained with X-Gal (VWR International). The TCID50
of the Lib4pp in TZM-bl was calculated using the method of Reed
and Meunch [67]. The titer determined in TZM-bl cells was
correlated to that in Huh-7.5 cells by comparing the infectivity of
GFP-expressing pseudoparticles (GFPpp) in both cell types.
GFPpp was generated using the same protocol but with the
replacement of Lib4-expressing plasmid with pTRIP-GFP [68].
Huh-7.5 and TZM-bl cells were inoculated with serial dilutions of
GFPpp (1021–1026). 48 hours later, Huh-7.5 cells were collected
and analyzed via flow cytometry (FACScan flow cytometer, BD
Biosciences) while infection of TZM-bl cells was analyzed as
described above. The infectivity of the pseudoparticles was
determined based on infection at low multiplicity of infection
(MOI) and correlated between these two cell lines.
Lentivirus pseudotyped with envelope proteins from HCV H77
(H77pp) [40] and VSV-G (VSV-Gpp) [41] were generated from
293T cells as previously described [65]. Both H77pp and VSV-
Gpp harbor the pTRIP-Gluc reporter provirus. Briefly, 293T cells
were transfected with a 1:4:1 mass ratio of HIV gag-pol, Gluc, and
H77/VSV envelope plasmids using TransIT-LT1 transfection
reagent [66]. Cell supernatants containing H77pp or VSV-Gpp
were collected 48 hours later, filtered and stored at 280uC until
use.
Library Selection
For each round of selection, 2.16107 n4mBid cells were
transduced with Lib4pp or repackaged lentiviral pseudoparticles
harboring enriched fragments at MOI ,0.5. This allowed for the
expression of each theoretical library fragment in at least 1000
cells on average. Cells were cultured for 48 hours post transduction
to allow for fragment expression. Next, these cells were challenged
with Jc1 HCVcc at MOI ,1, and cultured for 9 days or until
,10% of the initial cell population remained viable. Surviving
cells were ‘rescued’ from HCV infection by exposure to the HCV
polymerase inhibitor 29C-MA (1 mM) for 72 hours. Library
fragments in the surviving cell population were recovered by
transfecting these cells with plasmids encoding HIV gag-pol and
VSV-G using Fugene-6 transfection reagent (Promega). The
choice of the Fugene-6 reagent here derives from its low
cytotoxicity in these cells. Cell supernatants containing VSV-G-
coated pseudoparticles of repackegd fragments were collected 48
hours later, filtered and stored at 280uC. Since Huh-7.5 cells are
difficult to transfect, lentiviral pseudoparticles repackaged from
Huh-7.5 cells needed to be amplified prior to the subsequent
round of selection. Briefly, 293T cells were first transduced with
ten-fold diluted repackaged pseudoparticles. 48 hours later, these
cells were transfected with plasmids encoding HIV gag-pol and
VSV-G using Trans-IT LT1 transfection reagent (Mirus). Cell
supernatants containing high titers of repackaged Lib4pp were
collected 48 hours later, filtered and stored at 280uC. This
amplification step typically increases the lentiviral titer by ,100-
fold. Recovered supernatants were titered in TZM-bl cells as
described above and used for subsequent rounds of infection. After
the final round of selection, viral RNA were isolated using RNeasy
Mini Kit (Qiagen) and library fragment cDNA were amplified by
RT-PCR (ImProm-II, Promega) using the primers Lib4-F (59-
ACG GCC TCT AGA ATG AGC-39) and Lib4-R (59-AGT GGC
TAA GTC TAC AGC TG-39). Amplified fragments were
analyzed on a 1.5% agarose gel, as shown in Figure 1C.
Immunofluorescence Imaging and Western Blots
Huh-7.5 cells were seeded into wells of a glass chamber slide
before being transduced with lentiviral pseudoparticles expressing
Flag-tagged NS4Am-B1 and B1 (Constructs #3-4, Table 1). Two
days post transduction, cells were fixed by incubation with PBS/
2% PFA for 30 minutes at 4uC, stained with mouse anti-Flag
primary antibody (Genscript) and Alexa-Fluor 568-conjugated
goat anti-mouse secondary antibody (Life Technologies), treated
with antifade reagent (Promega) overnight and imaged using a
Zeiss 510 Meta NLO Multiphoton microscope (Carl Zeiss
Microscopy).
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For Western blots, cells were lysed with Renilla luciferase assay
lysis buffer (Promega) two days post transduction. Cell lysates were
combined with an equal volume of 2X SDS loading buffer and
incubated at 95uC for five minutes. Samples were resolved using
SDS-PAGE (12% acrylamide) and transferred to a PVDF
membrane. After transfer, the membranes were sequentially
incubated with mouse anti-Flag primary antibody (Genscript)
and HRP-conjugated donkey anti-mouse secondary antibody
(Jackson ImmunoResearch), developed using West Pico Chemilu-
minescent HRP substrate (Pierce) and visualized in a ChemiDoc-It
(UVP) chemiluminescence imager.
HCV Infection Assay
To evaluate the anti-HCV activity of B1, Huh-7.5 cells were
transduced with pLenti6-GFP/B1/NS4Am-B1pseudoparticles at
low (,0.5) MOI, selected with blasticidin (10 mg/mL) for 8 days
and inoculated with Jc1 Gluc HCVcc (MOI ,0.1), H77pp (10-
fold diluted supernatant) or VSV-Gpp (500-fold diluted superna-
tant) for 12 hours. The cells were thoroughly washed with
complete growth medium to remove residual Gluc protein and
HCV infectivity in each cell population was quantified 24 hours
later by measurement of the activity of the secreted Gluc reporter
protein in the supernatant.
HCV Replication and Translation Assay
Cells expressing eGFP or B1 were electroporated with the
genomic RNA of full-length Jc1 Gluc HCVcc [30]. Five hours post
electroporation, HCV translation was quantified by measurement
of reporter Gluc activity in the cell supernatants. Forty eight hours
post electroporation, cells were harvested and intracellular HCV
RNA levels were quantified by qRT-PCR as described previously
[65].
SINV Production and Infection Assay
Infectious SINV was generated and titered in BHK-J cells as
described previously [69]. Briefly, 16107 BHK-J cells were
suspended in 400 ml DPBS and electroporated with 3 mg in vitro-
transcribed SINV Toto1101 RNA [49] using an ECM 830
electroporator (Harvard Apparatus) programmed with the follow-
ing settings: 750 V, 99-ms pulse length, 5 pulses, 1.1-s interval. Cell
supernatants were collected 24 hours post electroporation, filtered
and stored at 280uC. SINV titers were determined by exposing
BHK-J cells to ten-fold serial dilutions of virus prior to
quantification via a plaque assay 24 hours later.
To evaluate the ability of B1 to inhibit SINV, BHK-J cells were
transduced with pV1-NS4Am-eGFP/B1 (Table 1, construct 1)-
expressing pseudoparticles at MOI ,4. Forty eight hours later,
these cells were infected overnight with SINV at MOI ,10. Cell
supernatants were collected 36 hours later upon cell lysis and the
amount of infectious SINV in each supernatant was quantified via
plaque assay.
Supporting Information
Figure S1 B1 nucleotide and amino acid sequences.
Image showing comparative nucleotide (black) and amino acid
(blue) sequences of eGFP (above) and B1 (below). Insertion which
lead to the generation of B1 is shown in red. Nucleotides encoding
NS4Am amino acids are highlighted in grey.
(TIF)
Figure S2 Intracellularly expressed +36GFP does not
inhibit HCV infection. Huh-7 cells were transduced with
lentiviral pseudoparticles expressing the indicated constructs at
MOI ,10. It was noted that using Huh-7 cells resulted in better
expression of the +36GFP construct. Two days later, cells were
exposed to HCVcc at MOI ,0.1 for 12 hours. Cell supernatants
were collected 48 hours post infection. At this time NS4Am-eGFP
and +36GFP expression were visualized with a fluorescence
microscope (A). After imaging, cells were trypsinized and the
percentage of +36GFP-expressing cells was quantified via flow
cytometry (B). HCV infection levels were quantified based on
secreted Gluc levels in the collected supernatants (C). Error bars
represent the standard deviation of two independent experiments
carried out in duplicate.
(TIF)
Figure S3 Purified B1 protein does not inhibit HCV
infection. Huh-7.5 cells were inoculated with Jc1 Gluc HCVcc
(A) or H77pp/VSV-Gpp (B) in the presence of the indicated
concentrations of GFP-L-B1, +36GFP or NH4Cl for 12 hours.
Subsequently, cells were washed and replenished with media
containing the same amounts of protein/drug. Levels of infection
in each cell population were quantified 48 hours later via
measurement of the secreted Gluc levels. Error bars represent
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